Beijing E-Town witnessed a booming momentum in the biotechnology and big health industry in the first quarter, with rapid growth in orders and continuous breakthroughs in research and development.

Guo Qian, founder of KeYi Medical Devices, stated, "Joint products are the main source of orders for the company, with a growth of 860 percent after centralized procurement, and the workshops are now in a state of saturated production." 

Since the beginning of this year, KeYi Medical Devices has increased its overall production capacity by 30 percent to 40 percent, with a maximum daily output of over 120 units on a single line, and an average of 100 sales orders being shipped from the workshop to various parts of the country every day.

In the workshop of KeYi Medical Devices, the neatly arranged automated CNC (Computer Numerical Control) equipment operates efficiently, with six production lines advancing simultaneously. [Photo/beijingetown.com.cn]

Another biotechnology company in Beijing E-Town, ICE Bioscience, has also experienced a rapid increase in order volume, with a growth of 1.5 times compared to the same period last year.

In addition to fulfilling orders, biopharmaceutical companies in Beijing E-Town remain unwavering in their research and development efforts.

The project with the fastest progress at Beijing Zhifei lvzhu Biopharmaceutical is the 23-valent pneumococcal polysaccharide vaccine, which has already applied for production registration and has been accepted, with the expectation of being listed this year.

"Our company's AI-assisted orthopedic treatment planning software has entered the green channel for innovative medical devices of the National Medical Products Administration, and is expected to obtain the registration approval for Class III medical devices and be listed this year." said the head of Changmugu Medical.

AcornMed recently published the world's first urine-based early screening and efficacy monitoring model for urothelial carcinoma in Molecular Cancer (IF=41.444) in collaboration with several well-known hospitals, with the highest impact factor in the field of early diagnosis and screening for urothelial carcinoma in the urinary tract. 

In addition, Tide Pharmaceutical has also obtained approval for the market launch of several new products.

"The smooth and positive development of enterprises cannot be achieved without the strong support of Beijing E-Town," said a head of a Beijing E-Town enterprise.

Kuaiteng Medical was greatly affected in terms of product export during the pandemic. "Fortunately, Beijing E-Town, coordinated in transportation, customs clearance, and other aspects, helped us to successfully complete the export tasks and reduce losses," according to a company spokesperson.

Du Lin, executive director of Beijing Zhifei lvzhu Biopharmaceutical, mentioned, "In the past two years, our company has received support from various policies of Beijing E-Town in terms of research and development, and production, including fixed asset investment rewards, output growth rewards, and research and development investment growth rewards, with a total of over 10 million yuan ($1.45 million) in supporting funds, which has relieved the financial pressure on the company and allowed us to focus on research and development."

LAMH relocates to a new address. [Photo/beijingetown.com.cn]

LAMH (Laboratory for Advanced Medicine & Health Group) recently relocated to a new research and development center in Beijing E-Town.

The head of the company remarked that, "After we made the demand for a new site, Beijing E-Town actively helped us coordinate and communicate, providing us with comprehensive and thoughtful services, which has further strengthened our confidence in long-term development here."

Furthermore, Beijing E-Town has issued a three-year action plan to emerge as a global industry highland of "intelligent manufacturing of new medicines", with "1+2" industrial policies to promote high-quality development of the healthcare industry. It will provide 1.123 million yuan in special incentive funds for 12 enterprises in the area to fulfill the "innovation growth plan" and "innovation partner plan", and issue over 12 million yuan in vocational skills training subsidies to enterprises. 

In addition, its "12 measures for industrial finance" have entered the stage of demand declaration, and application for innovative drug research and development rewards for 2022 has begun.